share_log

Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $91

Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $91

Chardan Capital維持對intellia therapeutics的買入評級,將目標價提高至91美元
Benzinga ·  11/18 23:23  · 評級/大行評級

Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $88 to $91.

Chardan Capital 分析師Geulah Livshits維持intellia therapeutics(納斯達克:NTLA)的買入評級,並將目標股價從88美元上調至91美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論